Innogen Pharmaceutical Names Jin Bai Vice President to Drive Commercialisation Strategy

Bulletin Express10-19

Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) has appointed Jin Bai as Vice President, effective 19 October 2026. Jin, 46, will oversee the overall commercialisation of the Group’s products and related operations.

The new executive brings more than two decades of experience in pharmaceutical sales and commercial management. From January 2025 to October 2026, Jin served as Chief Executive Officer and Chief Commercial Officer at Beijing Peak Biology Pharmaceuticals, with responsibilities spanning business operations, team development, market expansion and product collaborations.

Prior to that, Jin spent 19 years at AstraZeneca Investment (China) Co., Ltd. Starting as a sales representative in February 2006, he advanced through district and regional managerial roles before leading the company’s cardiovascular and community business units. Between October 2023 and January 2025, he headed the omnichannel community business unit, managing its sales, marketing, finance and human resources functions.

Innogen Pharmaceutical’s board stated that Jin’s extensive experience in commercial operations, team leadership and systematic management aligns with the Group’s global commercialisation objectives. The board has extended an official welcome to Jin upon his appointment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment